LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Pulmonx Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.75−0.03 (-1.69%)
Close on Oct 19, 2026
- Market cap
- $74.32M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
61.0%
26M of 43M shares
Institutional holders
108
20 new, 25 sold out
Net institutional buying
-6M
In Q2 2026
Insider trades, 12 months
0 buys · 55 sales
Net sold $547.89K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Primecap Management Co/Ca/ | 4,956,691 | 12.16% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson | 4,261,368 | 10.60% | 13G (passive) amendment | Jun 30, 2025 |
| Morgan Stanley | 2,920,241 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Soleus Capital Master Fund, L.P. | 2,665,100 | 6.50% | 13G (passive) | Mar 6, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LUNG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Primecap Management Co/Ca/ | 4,612,331 | 10.74% | $6.00M | −112,660 | 0.00% |
| Morgan Stanley | 2,922,921 | 6.81% | $3.80M | −1,070,641 | 0.00% |
| Soleus Capital Management, L.P. | 2,788,323 | 6.49% | $3.62M | – | 0.12% |
| Vanguard Capital Management LLC | 1,630,219 | 3.80% | $2.12M | −4,045 | 0.00% |
| ExodusPoint Capital Management, LP | 1,223,555 | 2.85% | $1.59M | −720,279 | 0.01% |
| Almitas Capital LLC | 1,064,202 | 2.48% | $1.38M | New | 0.33% |
| BlackRock, Inc. | 882,490 | 2.05% | $1.15M | −1,779,117 | 0.00% |
| Stonepine Capital Management, LLC | 815,436 | 1.90% | $1.06M | +47,148 | 0.60% |
| Jane Street Group, LLC | 758,231 | 1.77% | $985.70K | +624,961 | 0.00% |
| Braidwell LP | 752,541 | 1.75% | $978.30K | – | 0.04% |
| Aqr Capital Management LLC | 744,963 | 1.73% | $968.45K | +387,385 | 0.00% |
| Parkman Healthcare Partners LLC | 646,564 | 1.51% | $840.53K | −109,072 | 0.09% |
| Geode Capital Management, LLC | 452,684 | 1.05% | $588.71K | −491,808 | 0.00% |
| Renaissance Technologies LLC | 425,110 | 0.99% | $552.64K | +104,810 | 0.00% |
| ADAR1 Capital Management, LLC | 404,497 | 0.94% | $525.85K | +30,000 | 0.02% |
| Deutsche Bank AG\ | 402,316 | 0.94% | $523.01K | −761,362 | 0.00% |
| D. E. Shaw & Co., Inc. | 327,528 | 0.76% | $425.79K | −7,546 | 0.00% |
| Jefferies Financial Group Inc. | 285,110 | 0.66% | $370.64K | – | 0.00% |
| Cfm Wealth Partners LLC | 264,039 | 0.61% | $343.25K | – | 0.04% |
| Vanguard Fiduciary Trust Co | 250,511 | 0.58% | $325.66K | −30,737 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 108 | 26M | 61.0% | 20 / 36 | 35 / 25 | 4M | 10M |
| Q1 2026 | 114 | 32M | 74.0% | 22 / 38 | 37 / 17 | 5M | 3M |
| Q4 2025 | 112 | 32M | 75.5% | 24 / 30 | 38 / 18 | 7M | 6M |
| Q3 2025 | 107 | 32M | 75.3% | 20 / 35 | 29 / 26 | 5M | 9M |
| Q2 2025 | 113 | 36M | 84.4% | 23 / 34 | 35 / 25 | 4M | 4M |
| Q1 2025 | 115 | 36M | 84.6% | 15 / 42 | 31 / 17 | 4M | 4M |
| Q4 2024 | 118 | 36M | 83.9% | 23 / 36 | 34 / 15 | 3M | 4M |
| Q3 2024 | 113 | 37M | 85.3% | 27 / 37 | 30 / 22 | 7M | 3M |
| Q2 2024 | 112 | 36M | 83.4% | 21 / 40 | 32 / 26 | 5M | 9M |
| Q1 2024 | 118 | 40M | 93.7% | 18 / 35 | 42 / 22 | 8M | 4M |
| Q4 2023 | 123 | 36M | 84.3% | 21 / 42 | 37 / 13 | 8M | 4M |
| Q3 2023 | 117 | 33M | 77.5% | 11 / 39 | 44 / 9 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LUNG | Value | % of fund | As of |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Aggressive Growth Fund | 3,502,001 | 8.15% | $5.71M | 0.08% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,152,272 | 2.68% | $1.50M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 436,553 | 1.02% | $567.52K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 233,072 | 0.54% | $384.57K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 189,388 | 0.44% | $312.49K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 137,144 | 0.32% | $178.29K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 73,767 | 0.17% | $121.72K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 68,528 | 0.16% | $89.09K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 62,009 | 0.14% | $102.31K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 61,000 | 0.14% | $79.30K | 0.05% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 36,293 | 0.08% | $59.88K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 24,714 | 0.06% | $40.78K | 0.00% | May 31, 2026 |
| Large-Cap Growth Portfolio | 23,292 | 0.05% | $30.28K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 22,314 | 0.05% | $29.01K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 19,080 | 0.04% | $24.80K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Glendon E. French III | President and CEO, Director | 2,056,134 | 4.79% | Sep 3, 2026 |
| Steven S. Williamson | PRESIDENT AND CEO, Director | 363,497 | 0.85% | Sep 3, 2025 |
| David Aaron Lehman | General Counsel | 370,130 | 0.86% | Sep 3, 2026 |
| Srikanth Radhakrishnan | Chief Science & Techn. Officer | 326,475 | 0.76% | Sep 3, 2026 |
| Geoffrey Beran Rose | Chief Commercial Officer | 453,108 | 1.06% | Sep 3, 2026 |
| Derrick Sung | COO and CFO | 1,335,319 | 3.11% | Dec 3, 2025 |
| Mehul Joshi | Chief Financial Officer & PAO | 208,489 | 0.49% | Sep 3, 2025 |
| Thomas William Burns | Director | 113,399 | 0.26% | Jun 9, 2026 |
| Richard Ferrari | Director | 1,359,345 | 3.17% | Jun 9, 2026 |
| Georgia Melenikiotou | Director | 139,714 | 0.33% | Jun 9, 2026 |
| Dana G. Mead Jr. | Director | 143,790 | 0.33% | Jun 9, 2026 |
| Daniel P. Florin | Director | 149,699 | 0.35% | Jun 9, 2026 |
| Tiffany Sullivan | Director | 115,199 | 0.27% | Jun 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −2,121 | $2.26 | $4.79K | 326,475 |
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −3,618 | $2.26 | $8.18K | 322,857 |
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −5,863 | $2.26 | $13.25K | 316,994 |
| Srikanth Radhakrishnan Chief Science & Techn. Officer | Sep 1, 2026 | Sale | −2,643 | $2.26 | $5.97K | 328,596 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −2,224 | $2.26 | $5.03K | 370,130 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −3,476 | $2.26 | $7.86K | 366,654 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −4,827 | $2.26 | $10.91K | 361,827 |
| David Aaron Lehman General Counsel | Sep 1, 2026 | Sale | −3,807 | $2.26 | $8.60K | 372,354 |
| Glendon E. French III President and CEO, Director | Sep 1, 2026 | Sale | −37,784 | $2.26 | $85.39K | 1,137,936 |
| Glendon E. French III President and CEO, Director | Sep 1, 2026 | Sale | −4,098 | $2.26 | $9.26K | 1,175,720 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −2,390 | $2.26 | $5.40K | 453,108 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −1,746 | $2.26 | $3.95K | 449,832 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −1,530 | $2.26 | $3.46K | 451,578 |
| Geoffrey Beran Rose Chief Commercial Officer | Sep 1, 2026 | Sale | −2,213 | $2.26 | $5.00K | 455,498 |
| Thomas William Burns Director | Jun 5, 2026 | Award | +40,000 | – | – | 113,399 |
| Georgia Melenikiotou Director | Jun 5, 2026 | Award | +40,000 | – | – | 139,714 |
| Richard Ferrari Director | Jun 5, 2026 | Award | +40,000 | – | – | 127,024 |
| Tiffany Sullivan Director | Jun 5, 2026 | Award | +40,000 | – | – | 115,199 |
| Daniel P. Florin Director | Jun 5, 2026 | Award | +40,000 | – | – | 133,910 |
| Dana G. Mead Jr. Director | Jun 5, 2026 | Award | +40,000 | – | – | 139,714 |
| Glendon E. French III President and CEO, Director | Jun 2, 2026 | Sale | −13,511 | $1.57 | $21.21K | 1,178,162 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −2,434 | $1.54 | $3.75K | 459,965 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −2,254 | $1.54 | $3.47K | 457,711 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −1,778 | $1.54 | $2.74K | 463,956 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sale | −1,557 | $1.54 | $2.40K | 462,399 |
| Glendon E. French III President and CEO, Director | Jun 1, 2026 | Sale | −38,467 | $1.54 | $59.24K | 1,191,673 |
| Glendon E. French III President and CEO, Director | Jun 1, 2026 | Sale | −4,171 | $1.54 | $6.42K | 1,230,140 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −2,153 | $1.54 | $3.32K | 340,892 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −2,691 | $1.54 | $4.14K | 343,045 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −5,969 | $1.54 | $9.19K | 331,239 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Jun 1, 2026 | Sale | −3,684 | $1.54 | $5.67K | 337,208 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −2,264 | $1.54 | $3.49K | 384,615 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −3,876 | $1.54 | $5.97K | 386,879 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −4,915 | $1.54 | $7.57K | 376,161 |
| David Aaron Lehman GENERAL COUNSEL | Jun 1, 2026 | Sale | −3,539 | $1.54 | $5.45K | 381,076 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −2,590 | $1.43 | $3.70K | 244,806 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −4,051 | $1.43 | $5.79K | 240,755 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Award | +150,000 | – | – | 390,755 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −4,433 | $1.43 | $6.34K | 247,396 |
| David Aaron Lehman GENERAL COUNSEL | Mar 2, 2026 | Sale | −1,163 | $1.43 | $1.66K | 251,829 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −3,068 | $1.43 | $4.39K | 177,395 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −756 | $1.43 | $1.08K | 180,463 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Award | +175,000 | – | – | 345,736 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −2,461 | $1.43 | $3.52K | 174,934 |
| Srikanth Radhakrishnan Chief Science &Techn. Officer | Mar 2, 2026 | Sale | −4,198 | $1.43 | $6.00K | 170,736 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −1,861 | $1.43 | $2.66K | 368,645 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −835 | $1.43 | $1.19K | 372,631 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −2,125 | $1.43 | $3.04K | 370,506 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Award | +100,000 | – | – | 465,734 |
| Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Mar 2, 2026 | Sale | −2,911 | $1.43 | $4.16K | 365,734 |
| Glendon E. French III President and CEO, Director | Mar 2, 2026 | Sale | −6,737 | $1.43 | $9.63K | 1,467,879 |
| Glendon E. French III President and CEO, Director | Mar 2, 2026 | Sale | −2,708 | $1.43 | $3.87K | 1,474,616 |
| Glendon E. French III President and CEO, Director | Mar 2, 2026 | Sale | −58,368 | $1.43 | $83.47K | 1,409,511 |
| Daniel P. Florin Director | Dec 8, 2025 | Sale(10b5-1 plan) | −23,321 | $1.99 | $46.41K | 93,910 |
| Derrick Sung COO and CFO | Dec 1, 2025 | Award | +1,200,000 | – | – | 1,335,319 |
| Glendon E. French III President and CEO, Director | Dec 1, 2025 | Sale | −6,281 | $1.57 | $9.86K | 277,324 |
| Glendon E. French III President and CEO, Director | Dec 1, 2025 | Award | +1,200,000 | – | – | 1,477,324 |
| Glendon E. French III President and CEO, Director | Dec 1, 2025 | Sale | −2,524 | $1.57 | $3.96K | 283,605 |
| David Aaron Lehman GENERAL COUNSEL | Dec 1, 2025 | Sale | −3,401 | $1.57 | $5.34K | 252,992 |
| David Aaron Lehman GENERAL COUNSEL | Dec 1, 2025 | Sale | −976 | $1.57 | $1.53K | 262,294 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Williamson Steven Officer, Director | Jan 22, 2026 | 48,892 | $95.34K | Jan 22, 2026 | Restricted Stock |
| Williamson Steven Officer, Director | Jan 15, 2026 | 15,892 | $31.04K | Jan 15, 2026 | Restricted Stock |
| Williamson Steven Officer, Director | Jan 14, 2026 | 31,082 | $62.07K | Jan 14, 2026 | Restricted Stock |
| P. Florin Daniel Director | Dec 8, 2025 | 23,321 | $46.39K | Dec 8, 2025 | Restricted Stock |
| Richard Ferrari Director | Jun 13, 2025 | 5,438 | $16.37K | Jun 13, 2025 | Open Market Purchase |
| Ferrari Rich Director | Jun 12, 2025 | 8,000 | $25.31K | Jun 12, 2025 | Restricted Stock |
| French Glendon Director | Mar 20, 2025 | 60,000 | $466.20K | Mar 20, 2025 | Previously Exercised Options |
| Lehman David Officer | Mar 3, 2025 | 13,622 | $108.57K | Mar 3, 2025 | Restricted Stock |
| French Glendon Officer | Feb 20, 2025 | 55,453 | $368.21K | Feb 20, 2025 | Previously Exercised Options |
| French Glendon Director | Jan 17, 2025 | 2,221 | $14.21K | Jan 17, 2025 | Previously Exercised Options |
| French Glendon Director | Jan 16, 2025 | 2,326 | $15.63K | Jan 16, 2025 | Previously Exercised Options |
| French Glendon Officer | Nov 22, 2024 | 20,000 | $128.40K | Nov 22, 2024 | Previously Exercised Options |
| French Glendon Officer | Oct 17, 2024 | 20,000 | $136.00K | Oct 17, 2024 | Previously Exercised Options |
| French Glendon Director | Sep 12, 2024 | 20,000 | $155.00K | Sep 12, 2024 | Previously Exercised Options |
| B. Rose Geoffrey Officer | Jun 24, 2024 | 1,184 | $7.29K | Jun 24, 2024 | Exercised Shares |